Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Mabspace Reports Positive Data from Phase I Trial of 2nd-Gen PDL1

publication date: May 28, 2020

Mabspace Biosciences (Suzhou) reported positive results from a Phase I trial of its PDL1 targeting antibody in pre-treated patients with advanced solid tumors and hematological malignancies. Among the solid tumor group, patients who received the highest dose had an overall response rate of 33% (4/12), with three of the four responses lasting to data cutoff. Mabspace described MSB2311 as a second generation PD-L1 antibody that is the first in its class to have an pH-dependent antigen binding property. Mabspace is a subsidiary of China biopharma Transcenta Holding. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital